VIRGINIA RETIREMENT SYSTEMS ET Al Invests $4.44 Million in Moderna, Inc. $MRNA

VIRGINIA RETIREMENT SYSTEMS ET Al acquired a new stake in Moderna, Inc. (NASDAQ:MRNA) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 63,350 shares of the company’s stock, valued at approximately $4,436,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of MRNA. MUFG Securities EMEA plc acquired a new stake in Moderna in the 2nd quarter valued at about $28,000. Allied Private Wealth LLC acquired a new position in shares of Moderna during the second quarter worth about $30,000. Canton Hathaway LLC purchased a new stake in shares of Moderna during the first quarter worth approximately $31,000. Archer Investment Corp purchased a new stake in shares of Moderna during the second quarter worth approximately $36,000. Finally, EverSource Wealth Advisors LLC raised its holdings in Moderna by 148.3% in the second quarter. EverSource Wealth Advisors LLC now owns 1,341 shares of the company’s stock valued at $37,000 after acquiring an additional 801 shares in the last quarter. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on MRNA. UBS Group set a $81.00 price target on shares of Moderna in a research note on Thursday, September 3rd. Jefferies Financial Group restated a “hold” rating on shares of Moderna in a report on Wednesday, August 19th. Royal Bank Of Canada reaffirmed a “sector perform” rating and set a $130.00 price objective on shares of Moderna in a research report on Wednesday, August 19th. Brookline Capital Markets reiterated a “buy” rating on shares of Moderna in a research note on Wednesday, August 19th. Finally, Piper Sandler reissued an “overweight” rating on shares of Moderna in a report on Monday, August 3rd. Seven analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and five have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $76.72.

Moderna Stock Performance

Shares of Moderna stock opened at $135.61 on Thursday. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09. Moderna, Inc. has a 52 week low of $22.28 and a 52 week high of $176.66. The firm’s 50 day moving average is $89.93 and its two-hundred day moving average is $65.58. The firm has a market capitalization of $54.14 billion, a P/E ratio of -16.97 and a beta of 1.10.

Moderna (NASDAQ:MRNA) last issued its quarterly earnings data on Friday, July 31st. The company reported ($1.97) earnings per share for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The business had revenue of $145.00 million during the quarter, compared to the consensus estimate of $102.93 million. During the same quarter in the previous year, the firm earned ($2.13) EPS. The company’s revenue was up 2.1% compared to the same quarter last year. Research analysts forecast that Moderna, Inc. will post -6.09 EPS for the current fiscal year.

Insider Buying and Selling at Moderna

In other Moderna news, President Stephen Hoge sold 53,336 shares of the firm’s stock in a transaction dated Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares of the company’s stock, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The stock was sold at an average price of $139.95, for a total value of $485,766.45. Following the sale, the insider owned 74,129 shares in the company, valued at $10,374,353.55. This trade represents a 4.47% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 10.80% of the stock is owned by company insiders.

Moderna Profile

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.